People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| PanOptica, Inc. | — | Biotechnology | Series C | $57.3M | $1.7B | 2010 |
| BlinkBio, Inc. | — | Biotechnology | Series B | $43.6M | $20.8M | 2011 |
| OS Therapies Inc | — | Biotechnology | Series A | $29.7M | $4.7M | 2022 |
| Merganser Biotech, Inc. | — | Biotechnology | Series A | $21.1M | $473.5M | 2015 |
| Zelos Therapeutics Inc | — | Pharmaceuticals | Series A | $17.8M | $75.0M | 2009 |
Colin Goddard at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Colin Goddard on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Brian MacDonald | 2 | 4 |
| Jutta Wanner | 2 | 2 |
| James Topper | 1 | 12 |
| David Guyer | 1 | 8 |
| ABBIE CELNIKER | 1 | 6 |
| Mark Simon | 1 | 6 |
| Joseph Zakrzewski | 1 | 6 |
| Geoff Smith | 1 | 6 |
| Lutz Giebel | 1 | 6 |
| Farah Champsi | 1 | 5 |
| Jeffrey Bird | 1 | 5 |
| Thomas Dyrberg | 1 | 5 |
| Tracy Saxton | 1 | 5 |
| Bruce Peacock | 1 | 5 |
| Kevin Starr | 1 | 5 |
| Douglas Reed | 1 | 4 |
| Derek Small | 1 | 4 |
| Alan Lewis | 1 | 4 |
| Markus Goebel | 1 | 4 |
| Donald Hayden | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.